
    
      RAS Rosiglitazone and Atherosclerosis Study: A 1 year randomised, double-blind, parallel
      group, placebo controlled study to evaluate the efficacy of rosiglitazone on the progression
      of intima-media thickness in the carotid artery in subjects with insulin resistance syndrome
      and/or type 2 diabetes mellitus
    
  